Steinberg Global Asset Management Boosted By $307,440 Its Lazard LTD (LAZ) Position; Last Week Endocyte, Inc. (ECYT) Coverage

February 15, 2018 - By Dolores Ford

Steinberg Global Asset Management increased Lazard Ltd (LAZ) stake by 12.53% reported in 2017Q3 SEC filing. Steinberg Global Asset Management acquired 6,832 shares as Lazard Ltd (LAZ)’s stock rose 1.82%. The Steinberg Global Asset Management holds 61,363 shares with $2.78M value, up from 54,531 last quarter. Lazard Ltd now has $7.33 billion valuation. The stock increased 3.61% or $1.97 during the last trading session, reaching $56.48. About 763,903 shares traded or 4.58% up from the average. Lazard Ltd (NYSE:LAZ) has risen 35.63% since February 15, 2017 and is uptrending. It has outperformed by 18.93% the S&P500.

Among 4 analysts covering Endocyte (NASDAQ:ECYT), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Endocyte had 8 analyst reports since August 5, 2015 according to SRatingsIntel. As per Thursday, January 21, the company rating was initiated by Credit Suisse. The firm has “Hold” rating by Cowen & Co given on Monday, October 2. RBC Capital Markets maintained Endocyte, Inc. (NASDAQ:ECYT) on Wednesday, November 4 with “Outperform” rating. The firm has “Outperform” rating given on Wednesday, August 5 by RBC Capital Markets. The stock of Endocyte, Inc. (NASDAQ:ECYT) has “Neutral” rating given on Monday, June 5 by Wedbush. Cowen & Co maintained the shares of ECYT in report on Friday, June 2 with “Hold” rating. The stock has “Outperform” rating by Wedbush on Tuesday, October 3. The stock of Endocyte, Inc. (NASDAQ:ECYT) has “Market Perform” rating given on Monday, June 5 by Cowen & Co. See Endocyte, Inc. (NASDAQ:ECYT) latest ratings:

03/10/2017 Broker: Wedbush Old Rating: Neutral New Rating: Outperform Upgrade
02/10/2017 Broker: Cowen & Co Rating: Hold Maintain

The stock increased 2.58% or $0.08 during the last trading session, reaching $3.18. About 178,359 shares traded. Endocyte, Inc. (NASDAQ:ECYT) has declined 24.78% since February 15, 2017 and is downtrending. It has underperformed by 41.48% the S&P500.

Investors sentiment decreased to 0.32 in 2017 Q3. Its down 0.40, from 0.72 in 2017Q2. It is negative, as 14 investors sold Endocyte, Inc. shares while 24 reduced holdings. 4 funds opened positions while 8 raised stakes. 8.27 million shares or 31.84% less from 12.13 million shares in 2017Q2 were reported. Jacobs Levy Equity Management holds 29,041 shares or 0% of its portfolio. Fmr Ltd Liability Corp accumulated 2.44M shares or 0% of the stock. Prelude Capital Mgmt Lc reported 0% in Endocyte, Inc. (NASDAQ:ECYT). 2,000 were reported by Reilly Finance Advsr Ltd Limited Liability Company. Bnp Paribas Arbitrage Sa holds 0% or 74 shares in its portfolio. Bb&T Ltd invested in 0% or 20,750 shares. State Street holds 17,079 shares or 0% of its portfolio. 2,310 are held by Meeder Asset Mngmt Inc. Ameriprise Fincl stated it has 0% in Endocyte, Inc. (NASDAQ:ECYT). 18,610 were accumulated by Royal Financial Bank Of Canada. Goldman Sachs Gp stated it has 0% of its portfolio in Endocyte, Inc. (NASDAQ:ECYT). Anson Funds Mngmt L P has 0.04% invested in Endocyte, Inc. (NASDAQ:ECYT). Northern Trust reported 79,036 shares. Dimensional Fund Advsrs Limited Partnership reported 0% of its portfolio in Endocyte, Inc. (NASDAQ:ECYT). Yakira Capital Management reported 0.01% stake.

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company has market cap of $152.26 million. The firm uses its technology to create novel small molecule drug conjugates and companion imaging agents. It currently has negative earnings. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: